Adverse events/drug toxicity monitoring in tuberculosis treatment clinical trials(adults)

I am writing a systematic review on the general topic above, but I need to narrow it down to a question that can be answered by analyzing around a dozen clinical trial papers. Some things my supervisor suggested to consider: drug sensitive vs drug resistant patients, what phase clinical trials, the time frame of publication, whether to look at all adverse events or just one (eg hepatotoxicity). Please read the files “MD4002 handbook”, “Critical Appraisal”, and “Marking criteria” for details about the paper set by my course before starting. I have also attached info on how to do a systematic review, some background reading on tuberculosis, and clinical trial papers that my supervisor provided, which I think are useful. Note that the papers that are analyzed have to come from the literature search, but the RemoxTB paper by Stephen Gillespie should come up. Some databases(such as Ovid Medline) require an OpenAthens account to access. Most importantly, this needs to be original work because it will be put into a plagiarism detection software. Help with the 10 minute oral presentation(powerpoint) at the end would also be much appreciated. I would need to get weekly updates/drafts on the progress for my meetings with the supervisor. I would need a question, a search strategy(resulting in about a dozen papers to analyze), and data extraction for the final papers sent to me electronically. Please contact me if you need to access certain unavailable resources, as I might be able to.